Advertisement

Big pharma gets creative

With blockbuster drug patents set to expire in the next few years, big pharma is looking hard for ways to pack the discovery pipeline. One approach: the biotech model. Patrick Vallance, the head of drug discovery at GlaxoSmithKline, said at a meeting on Friday (June 6) that research at the company would be reorganized to be "more biotech-like," the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/a36193c0-366e-11dd-8bb8-0000779fd2ac.html?nclick_check=1 He said the plan was to split

By | June 10, 2008

With blockbuster drug patents set to expire in the next few years, big pharma is looking hard for ways to pack the discovery pipeline. One approach: the biotech model. Patrick Vallance, the head of drug discovery at GlaxoSmithKline, said at a meeting on Friday (June 6) that research at the company would be reorganized to be "more biotech-like," the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/a36193c0-366e-11dd-8bb8-0000779fd2ac.html?nclick_check=1 He said the plan was to split drug discovery into small units focused on specific disease areas, "and reward people based on successful value creation," while providing "disincentives" against destroying value. Another approach: the granting agency. Pfizer and the University of California, San Francisco, linkurl:announced a partnership;http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20080610006037&newsLang=en today (June 10) in which the company will contribute $9.5 million to early-stage research at the university over the next three years. Usually, industry funding targets specific projects, but in this case, researchers at the UCSF's Institute for Quantitative Biosciences will collaborate more broadly with the company, with both parties working together to identify promising ideas in different health disciples. Daniel Sanit, the institute's director, linkurl:told the San Francisco Chronicle;http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2008/06/09/BUA9114QQD.DTL that academic researchers and their institution will retain patents to any inventions, while Pfizer will have the right to negotiate licenses on the technology.
Advertisement

Comments

Avatar of: anonymous poster

anonymous poster

Posts: 4

June 11, 2008

I had to log in for this?????
Avatar of: null null

null null

Posts: 3

June 12, 2008

I do like these top mangers, who are able to put such spin on re-organisations at big pharma. Making them more like Biotech is pharma speak for " we are not making more of a profit than previously". "We have nothing decent in the pipeline". "The weak dollar is not helping". "We need to make some more redundancies, quick !"\nWhat a joke !
Avatar of: anonymous poster

anonymous poster

Posts: 2

June 17, 2008

According to ABN AMRO analysts, GSK's CEDD model has not boosted R&D productivity, so far, despite claims to the contrary of their outgoing CEO Garnier.

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Life Technologies